What's in Joseph L. Kuti, PharmD's pipeline?

Joseph L. Kuti, PharmD has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Joseph L. Kuti, PharmD's portfolio?

Top competitors by shared drug class: Evopoint Biosciences Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/joseph-l-kuti-pharmd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Joseph L. Kuti, PharmD — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Joseph L. Kuti, PharmD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Imipenem, Cilastatin and Relebactam	Imipenem, Cilastatin and Relebactam	marketed	Carbapenem antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase inhibition	Infectious Disease

Therapeutic area mix

Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Evopoint Biosciences Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Joseph L. Kuti, PharmD:

Cite this brief

Drug Landscape (2026). Joseph L. Kuti, PharmD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/joseph-l-kuti-pharmd. Accessed 2026-05-17.